Trials by Compound

Aprepitant

• Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Effects of Treatment With Aprepitant (EmendÂ) in HIV Infected Individuals
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Granisetron, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron in Preventing Nausea in Patients Undergoing Chemotherapy for Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Multi-day Doses in Prevention of Nausea and Emesis
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Palonosetron, Aprepitant, and Low-Dose Dexamethasone in Preventing Nausea and Vomiting in Patients Undergoing High-Dose Chemotherapy and Stem Cell Transplant fo...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
• A Randomized, Double-Blind Comparison of Oral Aprepitant Alone Versus Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiti...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Effectiveness of Aprepitant in the Treatment of Postoperative Nausea and Vomiting (PONV) in Patients Undergoing Outpatient Plastic Surgery
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Observational Study of Delayed Nausea and Vomiting
• Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Study of Aprepitant (MK0869) and Fosaprepitant (MK0517) in Pediatric Patients Receiving Chemotherapy
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Study of Aprepitant (MK0869) in Pediatric Patients Undergoing Surgery
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
• Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
• The Effect of NK1R Antagonism on Alcohol Craving and PTSD Symptoms in Alcohol Dependent Patients With PTSD
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
• Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy
• Effects of Substance P Antagonists on Adrenal Secretion
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

MK-0646 (Insulin-Like Growth Factor Receptor Inhibitor)

• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
• Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer
• Phase I Imaging Study Evaluating MK0646 in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer
• A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer
• A Study of MK0646 in Breast Cancer Patients
• MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
• MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer
• Phase I Study of Dalotuzumab (MK0646) in Combination With Cetuximab and Irinotecan in Colorectal Cancer Patients

MK-0752 (Gamma-Secretase (Notch) Inhibitor)

• A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer
• MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
• Phase I/II Study of MK-0752 Followed by Docetaxel in Advanced or Metastatic Breast Cancer
• Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer
• A Phase I Study of MK-0752 in Pediatric Patients With Recurrent or Refractory CNS Malignancies

MK-1496 (PLK1)

• Phase I Study of MK1496 in Patients With Advanced Solid Tumor

MK-8033 (cMET)

• A Study of MK8033 in Patients With Advanced Solid Tumors

MK-8669,AP23573

• Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer

MK1775

• A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors

MK2206

• Dose Escalation Study With MK2206 in Patients With Locally Advanced or Metastatic Solid Tumors
• A Phase I Study of MK2206 in Combination With Standard Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
• A Study of MK2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors
• A Combination Therapy Study of MK2206 and AZD6244 in Patients With Advanced Solid Tumors

MK4827

• MK4827 in Patients With Advanced Solid Tumors

MK5108

• Treatment of Patients With Advanced and/or Refractory Solid Tumors

SCH 727965

• Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630AM6)

V934/935 (vaccine for cancers expressing hTERT)

• A Study of V934/V935 in Cancer Patients With Selected Solid Tumors (Merck)

Vorinostat

• Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Suberoylanilide Hydroxamic Acid Vorinostat, MK0683 Versus Placebo in Advanced Malignant Pleural Mesothelioma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lympho...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Treating Patients With Kidney Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
• Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Dis...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Clinical Trial of SAHA in Patients With Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Palliative Radiotherapy
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
• Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
• Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Bortezomib as Third-Line Treatment in Advanced Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat Plus Radiation Therapy in Pancreatic Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Phase I Study of MK0683 in Combination With Bortezomib in Multiple Myeloma Patients
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Study of Vorinostat (MK0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) or Mantle Cell Lymphoma (MCL) Patients
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Decitabine, Vorinostat, and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma That Has Relapsed or Not R...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritonea...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small L...
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
• Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
• Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
  This trial offers additional enrollment services. Call 866-890-6619 or click here
• Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

ridaforolimus

• Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus)
• A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
• Clinical Trial of Riadaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma
• Deforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
• Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers
• A Study of Ridaforolimus in Non-Small Cell Lung Cancer Patients With KRAS Mutations
• A Study to Evaluate the Effect of MK8669 on QTc Interval in Patients
• Study of MK8669 With Metastatic Bone or Soft-tissue Sarcoma Patients